135861-04-0Relevant articles and documents
METALLOENZYME INHIBITOR COMPOUNDS
-
Paragraph 0629; 0630; 0631, (2018/07/29)
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND, AND RADIOACTIVE PHARMACEUTICALS CONTAINING THE SAME
-
Paragraph 0073; 0076, (2018/10/16)
PROBLEM TO BE SOLVED: To provide a radioactive compound which has higher selectivity for CYP11B2 than for CYP11B1, and higher accumulation selectivity for adrenal gland than for blood and neighboring organs. SOLUTION: The present invention provides a radioactive compound of a 2-(3-pyridinyl)-1H-benzimidazole derivative represented by a prescribed general formula or a salt thereof, and pharmaceuticals containing these. COPYRIGHT: (C)2016,JPOandINPIT
Pyrimido[1,6-a]benzimidazoles: A new class of DNA gyrase inhibitors
Hubschwerlen,Pflieger,Specklin,Gubernator,Gmunder,Angehrn,Kompis
, p. 1385 - 1392 (2007/10/02)
Substituted 4-quinolone- (1, A = CH) and 1,8-naphthyrid-4-one- (1, A = N) 3-carboxylic acids are currently the only classes of clinically useful antibacterial agents exerting their activity by inhibiting the subunit A of DNA gyrase. Pyrimido[1,6-a]benzimi